Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer

被引：25

作者：

Tang, Chad ^{[1
]}

Chan, Cato ^{[1
]}

Jiang, Wen ^{[1
]}

Murphy, James D. ^{[1
]}

von Eyben, Rie ^{[1
]}

Colevas, A. Dimitrios ^{[3
]}

Pinto, Harlan ^{[3
,4
]}

Lee-Enriquez, Nancy ^{[1
]}

Kong, Christina ^{[2
]}

Quynh-Thu Le ^{[1
]}

机构：

[1] Stanford Univ, Dept Radiat Oncol, Stanford, CA 94305 USA

[2] Stanford Univ, Dept Pathol, Stanford, CA 94305 USA

[3] Stanford Univ, Div Med Oncol, Dept Med, Stanford, CA 94305 USA

[4] Vet Adm Palo Alto Heath Care Syst, Palo Alto, CA USA

来源：

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2015年 / 37卷 / 03期

关键词：

head and neck cancer; cetuximab; chemoradiation; platinum-based chemotherapy; human papillomavirus; HUMAN-PAPILLOMAVIRUS; PLUS CETUXIMAB; RADIOTHERAPY; CHEMOTHERAPY;

D O I：

10.1002/hed.23609

中图分类号：

R76 [耳鼻咽喉科学];

学科分类号：

100213 ;

摘要：

BackgroundThe purpose of this study was to present our experience utilizing cetuximab and platinum-based concurrent chemoradiotherapy for the definitive treatment of head and neck squamous cell carcinoma (HNSCC). MethodsPatients (n = 177) who received definitive concurrent chemoradiotherapy for HNSCC were stratified into 3 groups: receiving cetuximab monotherapy (n = 24), cetuximab and chemotherapy combination (n = 33), or platinum-based chemotherapy without cetuximab (n = 120). Primary endpoints were freedom from relapse, event-free survival, and overall survival (OS). ResultsPatients receiving cetuximab monotherapy were older with lower Karnofsky performance status (KPS) and higher Charlson comorbidity scores compared with those treated with combination cetuximab and chemotherapy or platinum-based concurrent chemoradiotherapy. Patients treated with platinum-based concurrent chemoradiotherapy exhibited significantly better freedom from relapse, event-free survival, and OS compared with those receiving cetuximab monotherapy or cetuximab and chemotherapy combination therapies (all p < .05). Differences between patients receiving cetuximab monotherapy and platinum-based concurrent chemoradiotherapy held on multivariate Cox regression. ConclusionThis study suggests that platinum-based concurrent chemoradiotherapy is superior to cetuximab-based monotherapy for the definitive treatment of HNSCC. (c) 2014 Wiley Periodicals, Inc. Head Neck 37: 386-392, 2015

引用

页码：386 / 392

页数：7

共 50 条

[1] Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer
Beckham, Thomas H.
Barney, Christian
Healy, Erin
Wolfe, Adam R.
Branstetter, Andrew
Yaney, Alexander
Riaz, Nadeem
McBride, Sean M.
Tsai, C. Jillian
Kang, Julie
Yu, Yao
Chen, Linda
Sherman, Eric
Dunn, Lara
Pfister, David G.
Tan, Jeremy
Rupert, Robert
Bonomi, Marcelo
Zhang, Zhigang
Lobaugh, Stephanie M.
Grecula, John C.
Mitchell, Darrion L.
Wobb, Jessica L.
Miller, Eric D.
Blakaj, Dukagjin M.
Diavolitsis, Virginia M.
Lee, Nancy
Bhatt, Aashish D.
[J]. INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (01) : 107 - 115
[2] Concurrent Cetuximab and Radiation Therapy in Patients with Locoregionally Advanced Head and Neck Cancer
Cheng, H. C.
Ngan, R. K. C.
Au, K. H.
[J]. HONG KONG JOURNAL OF RADIOLOGY, 2012, 15 (01): : 29 - 35
[3] Platinum-based chemotherapy plus cetuximab in head and neck cancer
Vermorken, Jan B.
Mesia, Ricard
Rivera, Fernando
Remenar, Eva
Kawecki, Andrzej
Rottey, Sylvie
Erfan, Jozsef
Zabolotnyy, Dmytro
Kienzer, Heinz-Roland
Cupissol, Didier
Peyrade, Frederic
Benasso, Marco
Vynnychenko, Ihor
De Raucourt, Dominique
Bokemeyer, Carsten
Schueler, Armin
Amellal, Nadia
Hitt, Ricardo
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (11): : 1116 - 1127
[4] Low-Dose Weekly Platinum-Based Chemoradiation for Advanced Head and Neck Cancer
Watkins, John M.
Zauls, A. Jason
Wahlquist, Amy H.
Shirai, Keisuke
Garrett-Mayer, Elizabeth
Gillespie, M. Boyd
Day, Terry A.
Sharma, Anand K.
[J]. LARYNGOSCOPE, 2010, 120 (02): : 236 - 242
[5] Concurrent cetuximab versus platinum-based chemotherapy with radiotherapy for patients with squamous cell carcinoma of the head and neck
Caudell, J. J.
Sawrie, S. M.
Spencer, S. A.
Carroll, W. R.
Peters, G. E.
Nabell, L. M.
Meredith, R. F.
Bonner, J. A.
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 69 (03): : S451 - S451
[6] Cetuximab in the management of locoregionally advanced head and neck cancer: Expanding the treatment options?
Bourhis, Jean
Lefebvre, Jean-Louis
Vermorken, Jan B.
[J]. EUROPEAN JOURNAL OF CANCER, 2010, 46 (11) : 1979 - 1989
[7] Cetuximab versus Platinum-based Chemoradiation in Locally Advanced p16 Positive Oropharyngeal Cancer
Barney, C.
Walston, S.
Zamora, P.
Nolan, N.
Diavolitsis, V.
Blakaj, D.
Wobb, J.
Mitchell, D.
Grecula, J.
Savvides, P.
Bhatt, A.
[J]. RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S174 - S175
[8] Concurrent Radiotherapy With Cetuximab or Platinum-based Chemotherapy for Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck
Lu, Sharon M.
Lien, Winston W.
[J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2018, 41 (01): : 95 - 99
[9] Weekly Versus Every 3 Weeks Platinum-Based Chemoradiation Regimens for Head and Neck Cancer
Melotek, J. M.
Cooper, B. T.
Koshy, M.
Silverman, J. S.
Spiotto, M. T.
[J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E328 - E329
[10] Cisplatin-Based Chemotherapy versus Cetuximab in Concurrent Chemoradiotherapy for Locally Advanced Head and Neck Cancer Treatment
Hu, Ming-Hung
Wang, Ling-Wei
Lu, Hsueh-Ju
Chu, Pen-Yuan
Tai, Shyh-Kuan
Lee, Tsung-Lun
Chen, Ming-Huang
Yang, Muh-Hwa
Chang, Peter Mu-Hsin
[J]. BIOMED RESEARCH INTERNATIONAL, 2014, 2014

← 1 2 3 4 5 →